Abstract | p21-activated kinases (PAKs) are positioned at the nexus of several oncogenic signalling pathways. Overexpression or mutational activation of PAK isoforms frequently occurs in various human tumours, and recent data suggest that excessive PAK activity drives many of the cellular processes that are the hallmarks of cancer. In this Review, we discuss the mechanisms of PAK activation in cancer, the key substrates that mediate the developmental and oncogenic effects of this family of kinases, and how small-molecule inhibitors of these enzymes might be best developed and deployed for the treatment of cancer.
Several protein kinases have been identified as drivers of the growth, survival and spread of human cancers. Many oncogenic kinases have been successfully targeted by drugs, but resistance is common and there is a need for additional targets and agents. p21-activated kinases (PAKs) are serine/threonine-specific intra cellular protein kinases that are positioned at the intersection of several signalling pathways that are required for oncogenesis. When overexpressed, or when aberrantly activated by mutation or by upstream elements such as the small GTPases RAC or cell division control protein 42 (CDC42), most PAK isoforms have oncogenic signalling effects in cells, which include the acquisition of growth signal autonomy, evasion of apoptosis and the promotion of invasion and metastasis (FIG. 1) . For these reasons, it is important to understand the mechanisms of PAK activation in cancer, the key substrates that mediate the developmental and oncogenic effects of these kinases and the potential value of PAKs as drug targets for the treatment of cancer.
The six mammalian PAKs can be categorized into two subgroups on the basis of their sequence and structure: group I comprises PAK1, PAK2 and PAK3; group II comprises PAK4, PAK5 and PAK6. These two subgroups have both overlapping and distinct functions, and they are regulated by different autoinhibitory mechanisms that can be exploited for the design of specific small-molecule inhibitors
. Gene-knockout mouse models clearly show the distinct roles of PAK family members in normal tissue development, with phenotypes that range from no apparent effect to early embryonic death (TABLE 1) . The development of such models has also underscored the unique involvement of each PAK family member in cancer pathophysiology. In addition, these models allow a better understanding of signalling deregulation in PAK-active tumour cells, which may lead to new opportunities for targeted anticancer therapy.
Upregulation of PAK in cancer
PAK function is increased in many human cancers and generally has a positive correlation with advanced tumour grade and decreased patient survival 1, 2 . The mechanisms that underlie increased PAK activity most often involve the gene amplification of PAK1 on chromosome 11q13 or PAK4 on chromosome 19q13
, although in some circumstances PAK mRNA and/or PAK protein may be overexpressed in the absence of gene amplification. In addition, PAKs can be hyperactivated by mutations in upstream regulators such as RAC or its exchange factors. For all of these mechanisms except mutations in upstream regulators, it is assumed that overexpression of wild-type PAK will increase its activity as a result of increased enzyme concentrations. Activating point mutations in the PAK4 and PAK5 (also known as PAK7) genes have recently been described in association with colon and lung cancers, but these mutations have not yet been validated as drivers of tumour formation [3] [4] [5] [6] . Interestingly, using an unbiased search for protein kinases that can transform immortalized human mammary epithelial cells, it has been reported that PAK1 has a powerful effect on the acquisition of anchorage independence and on other hallmark properties of transformed cells 7 . In this study, the authors showed that overexpression of PAK1 (which occurs in most chromosome 11q13-amplified breast cancers) simultaneously augmented the activation of ERK and MET (the receptor for hepatocyte growth factor (HGF)) signalling; MET is activated via the inhibition of the tumour suppressor 
Cyclin D1
A cyclin that, in partnership with cyclin-dependent kinases, is a key protein in progression through the G1 phase of the cell cycle. The gene encoding this protein (CCND1) is frequently co-amplified with the p21-activated kinase 1 (PAK1) gene in human cancers.
protein merlin (also known as neurofibromin 2) (FIG. 2) . Importantly, disruption of ERK or MET signalling inhibited PAK1-driven anchorage-independent growth. In addition, the results of this study and other studies of chromosome 11q13-amplified cells are consistent with the idea of PAK1 'addiction' , because these cells showed considerable sensitivity to PAK1-targeting (but not PAK2-targeting) small interfering RNA 7, 8 . Given that most PAKs have important scaffolding functions (in addition to catalytic activity), it will be important to determine whether PAK1-amplified cells also show increased sensitivity to small-molecule inhibitors that target PAKs. If so, the presence of PAK1 amplification might be used as a useful patient-selection criterion for designing clinical trials of drugs that target PAK1.
Regulation at the transcriptional level has not been described in detail for any of the PAK isoforms. PAK1 mRNA has been reported to be a target of miR-7 and also let-7, which is a microRNA (miRNA) that is thought to have a role as a tumour suppressor in several human malignancies 9, 10 . The expression of PAK2 and PAK4 has also been shown to be regulated by miRNAs [11] [12] [13] . In addition, PAK3 transcription was recently reported to be regulated by activator protein 1 (AP1) 14 . Owing to reports that the expression of certain PAK genes is increased by oncogenic signals 15 , we can expect that future work will identify additional cancer-relevant regulators of PAK transcription or translation.
Promoting growth signal autonomy
In most cell types, PAK isoforms, with the possible exception of PAK2 , promote cell cycle progression when they are overexpressed, and hinder such progression when they are removed or inhibited 15, 19, 20 . These observations, together with the fact that PAK genes are frequently amplified (PAK1 and PAK4) or mutated (PAK5) in human cancers, are consistent with a role for these enzymes in promoting oncogenesis by stimulating cell proliferation in the absence of growth signals. The mechanisms that underpin this aspect of PAK signalling are fairly well understood because PAKs have been shown to activate components of the ERK, AKT and WNT signalling pathways, all of which are closely tied to cell cycle progression (FIG. 2) . In the ERK pathway, various PAK isoforms have been shown to phosphorylate CRAF (also known as RAF1) at Ser338 and MEK1 at Ser298. Although it has been proposed that these phosphorylation events are required for efficient ERK activation and subsequent expression of cyclin D1, which is a key driver of cell cycle (G1 phase) progression, there are several puzzling aspects to this model that remain unresolved. For example, it has recently been reported that over expression of kinase-dead forms of PAK1 can activate ERK in the absence of phosphorylation of CRAF on Ser338 (or the equivalent phosphorylation of BRAF on Ser445), perhaps by functioning as a scaffold to facilitate RAF-MEK interaction 21 . In addition, MEK1 Ser298 phosphorylation has been shown to be dispensable for ERK activation in some circumstances 22 . Some of these issues may relate to artefacts of overexpression, but most of the data suggest that, in addition to their kinase activity, PAK scaffolding functions contribute to proliferative signal transduction. Such kinase-independent mechanisms have also been invoked to explain the positive effects of PAK on AKT activity and cell survival. In this case, formation of a PAK1-3-phosphoinositidedependent protein kinase 1 (PDPK1) complex is thought to promote recruitment of AKT to the plasma membrane and subsequent AKT activation 23 . Using a KRAS-driven transgenic mouse model of skin cancer, it was been reported that Pak1 deletion delayed both cancer initiation and progression, blocked G1 phase progression and nearly eliminated the activation of ERK and AKT by KRAS 24 (TABLE 1) . Treatment of these mice with either of two distinct, fairly specific small-molecule inhibitors of PAK (see below) recapitulated these phenomena and thereby established PAK1 as a potential drug target in KRAS-driven cancers. Treatment with ERK or AKT pathway-selective small-molecule inhibitors showed that the major antitumour effect in this model was related to loss of the ERK rather than to loss of the AKT branch of the KRAS signalling pathway. These data show that, in this genetically engineered mouse model of cancer, PAK1 regulates the activation of both ERK and AKT by KRAS, but it is the ERK effects that are more crucial for tumorigenesis. Whether these conclusions regarding the mechanism will generally apply to KRAS transformation is unclear, as it has been recently reported that depletion of PAK1 or PAK4 in KRAS-or BRAF-mutant colon cancer cells resulted in decreased proliferation, but that this occurred by a mechanism that was independent of the ERK pathway 25 . Several groups have recently uncovered interactions of PAK with the WNT-β-catenin pathway [26] [27] [28] . PAK1 associates with and phosphorylates β-catenin on at least two sites, Ser663 and Ser675, and these phosphorylation events stabilize β-catenin and promote both its relocalization to the nucleus and subsequent transcriptional activity, including upregulation of MYC and cyclin D1 (REF. 26) (FIG. 2) universal among all of the members of the PAK family because PAK2 depletion has no effect on β-catenin expression levels or phosphorylation in breast epithelial cells 26 . In contrast to the aforementioned KRAS skin cancer model, in ERBB2 (also known as HER2)-transformed breast epithelial cells, the role of PAK1 in stabilizing β-catenin seems to be more important than its effects on either ERK or AKT activation, because a loss of either PAK1 or PAK2 reduces the activity of ERK and AKT but only PAK1 loss leads to the destabilization of β-catenin and to growth arrest. These data show that different cell types and/or different oncogenic drivers probably deploy PAK signalling in unique and not yet predictable patterns, and this emphasizes the need to assess various tumour models when evaluating the therapeutic potential of PAK isoforms or when evaluating the entire PAK family as drug targets in cancer.
Interestingly, in Drosophila melanogaster, the group II PAK Mushroom bodies tiny (Mbt; which is most similar to vertebrate PAK4) has been shown to phosphorylate the β-catenin orthologue Armadillo at two sites; one of these sites is equivalent to mammalian β-catenin Ser675. Phosphorylation at these two sites destabilizes the interactions of Armadillo with D. melanogaster E-cadherin and thereby decreases cell-cell adhesion 30 . In mammalian cells, it is unclear whether PAK-induced loss of β-catenin from adhesion sites, as opposed to increased transcription of β-catenin target genes in the nucleus, mediates any of the effects of PAKs on transformation.
Other cell cycle-related targets of PAK include nuclear hormone receptors, Aurora kinase A (AURKA) and polo-like kinase 1 (PLK1) [31] [32] [33] [34] . PAK1 phosphorylates the oestrogen receptor (ER) at Ser305, which promotes its activation and subsequent signalling through cyclin D1 (REF. 33 ). This event is linked to tamoxifen resistance in ER-positive breast tumours that are insensitive to hormone-based therapies, which suggests that PAK1 inhibition might be beneficial in the treatment of tamoxifen-resistant breast cancer 19, 35 . In addition, PAK6 has been shown to inhibit the activity of the androgen receptor 34 . The phosphorylation of PLK1 and AURKA by PAK1 regulates cell cycle proliferation by affecting cytokinesis and mitotic entry 31, 32 . PAK4 augments the G1/S phase transition by downregulating the transcription of cyclin-dependent kinase inhibitor 1A (CDKN1A; which encodes p21) 36 , although the details that underlie this phenomenon have not been described. In Xenopus laevis oocyte extracts, pak4 has also been shown to regulate the G2/M phase transition by phosphorylating the small GTPase ran, and this event impedes the binding of ran to the guanine nucleotide exchange factor (GEF) regulator of chromosome condensation (rcc1), which interferes with nucleotide exchange and the ability of ran to facilitate the assembly of microtubule asters during mitosis 37, 38 . These mechanisms may explain the mitotic arrest that is observed in PAK4-depleted cells.
Promoting cell survival
Several members of the PAK family have been shown to inhibit apoptosis. Some of these anti-apoptotic effects are mediated by phosphorylation of BAD, which prevents BAD from binding to BCL-2, thereby inhibiting apoptotic signalling 39 . The phosphorylation of BAD is regulated by PAK in at least two ways. First, CRAF is a known substrate of PAK1, PAK2 and PAK5 (REFS 40, 41) . PAK-mediated phosphorylation of CRAF at Ser338 results in its translocation to the mitochondria and subsequent binding to and phosphorylation of BAD 41 . PAKs have also been shown to directly phosphorylate BAD 39 . Reports that PAK1 regulates apoptosis by phosphorylating dynein light chain 1 (DLC1; also known as DYNLL1) at Ser88 are difficult to reconcile with the results of a study showing that the purported phosphorylation site on DLC1 lies within a poor PAK consensus motif, that native (non-glutathione S-transferase (GST)-fused) DLC1 is not modified by PAK1 in vitro and that phosphorylation of DLC1 on Ser88 is not represented in mass spectroscopy phosphoproteome databases 42 . Nevertheless, PAK1 clearly binds to DLC1 (REFS 42, 43) and in this complex it seems to hinder the ability of the BIM isoform BIM L to bind to BCL-2, thus impeding apoptotic signalling 43 . It has been also shown that PAK activates the nuclear factor-κB (NF-κB) pathway. Activation of NF-κB signalling by PAK1 has been shown to increase the resistance Substrates of group I and II p21-activated kinases (PAKs) are shown according to their putative roles in oncogenic signalling. In some cases (for example, CRAF), substrates have roles in multiple cellular functions but they are listed only once to avoid visual clutter. PAK substrates are included only if they have been reported by more than one group or if the reported site of phosphorylation is represented in the PhosphoSitePlus database. AR, androgen receptor; ARPC1B, actin-related protein 2/3 complex subunit 1B; CALD1, caldesmin 1; ER, oestrogen receptor; FLNA, filamin A; GAP15, GTPase-activating protein 15; GEF, guanine nucleotide exchange factor; GIT1, ARF GTPase-activating protein; H3, histone 3; LIMK1, LIM domain kinase 1; MLC, myosin light chain; MLCK, myosin light chain kinase; MORC2, MORC family CW-type zinc finger protein 2; NCF1, neutrophil cytosol factor 1; NCOA3-Δ4, nuclear receptor coactivator 3 Δ4 splice variant (also known as SRC3-Δ4); PACSIN1, protein kinase C and casein kinase substrate in neurons protein 1; PLK1, polo-like kinase 1; SSH, slingshot; STMN1, stathmin 1; VE-cadherin, vascular endothelial-cadherin; VIM, vimentin. 
Kaposi's sarcoma-associated herpesvirus
The human herpesvirus that causes Kaposi's sarcoma.
Nuclear blebbing
Vesicular outpocketing of the nuclear membrane that is a hallmark of apoptosis.
to apoptosis in mammary epithelial cells 44 and to be required for transformation by Kaposi's sarcoma-associated herpesvirus 45 . However, the mechanism or mechanisms that underlie NF-κB pathway activation are still unclear because a convincing direct PAK1 target in this pathway has yet to be identified. However, it is known that in endothelial cells PAK1 somehow modulates the ability of reactive oxygen species to activate NF-κB in response to disturbances in blood flow 46 . This phenomenon is probably relevant to several aspects of tumorigenesis, including cell survival, angiogenesis and inflammation.
Mainly on the basis of in vitro overexpression studies PAK2 has been shown to have both anti-apoptotic and pro-apoptotic functions. Inhibition of apoptosis occurs through mechanisms that are similar to those that have been described for PAK1, but it has also been proposed that PAK2 can phosphorylate caspase 7 at Ser30, Thr173 and Ser239, thereby decreasing the pro-apoptotic activity of caspase 7 (REF. 47 ). However, late in apoptosis PAK2 itself is cleaved by caspase 3 or caspase 3-like proteases, and this liberates the kinase domain from the regulatory domain 48 . The resulting proteolytic fragment, PAK2-p34, which contains the protein kinase domain, induces nuclear blebbing and reduced protein synthesis that is mediated by phosphorylation of MAPK-interacting serine/threonine protein kinase 1 (MNK1; also known as MKNK1) 49 . Interestingly, conditional activation of PAK2 in Hs578T human breast carcinoma cells suppresses the activation of caspase 3, the generation of PAK2-p34 and apoptosis in response to the anticancer drug cisplatin 50 . These data suggest a feedback process in which PAK2 promotes survival, partly by suppressing its own cleavage to a pro-apoptotic fragment.
Much less is known about the mechanisms by which group II PAKs augment cell survival. However, there are indications that at least some of these mechanisms differ
Box 1 | Mechanisms of PAK activation
All p21-activated kinases (PAKs) have a conserved carboxy-terminal serine/threonine kinase domain with a single phosphorylation (P) site and an amino-terminal regulatory domain. The regulatory domain of group I PAKs (PAK1-3) is structurally distinct from that of group II PAKs (PAK4-6), and this is consistent with the different mechanisms that regulate the activity of these proteins.
The three group I PAKs are thought to be regulated via a trans autoinhibition mechanism 113 . The N-terminal p21 GTPase-binding domain (GBD) overlaps with an autoinhibitory domain (AID) (see the figure, part a) . PAK folds into an inactive homodimer, wherein the AID domain binds to the kinase domain of its partner. Binding of active RHO GTPases such as cell division control protein 42 (CDC42) and RAC1 to the GBD, and concomitant binding of phosphoinositide to an adjacent segment that is rich in basic amino acids, leads to dissociation of the AID from the kinase domain, reorganization of the dimer and subsequent autophosphorylation [114] [115] [116] . When the phosphorylated kinase domain binds to a substrate, it adopts a monomeric conformation 114 . Subsequent autophosphorylation at multiple sites stabilizes this catalytically active state. Additional mechanisms can also modify group I PAK activity and function. These mechanisms include transphosphorylation by other kinases and the binding of phospholipids, the exchange factor β-PIX and SRC-homology 3 (SH3) domain-containing proteins such as the adaptor proteins NCK adaptor protein 1 (NCK1) and growth factor receptor-bound protein 2 (GRB2) [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] . The mechanism (or mechanisms) of activation of group II PAKs is less clear (see the figure, part b) . In contrast to group I PAKs, the kinase domain of the group II PAKs is constitutively phosphorylated 126 . Hence, transition to the active form probably depends on conformational changes. Until recently, it was believed that group II PAKs, with the possible exception of PAK5 (REF. 127 ), lacked an AID and that interactions with CDC42 mainly functioned to determine subcellular localization 128, 129 . However, a recent study proposed that there is an AID in the N terminus of PAK4 that inactivates the kinase domain in cis until GTP-bound CDC42 binds the GBD and allows activation 126 . An alternative model proposes that PAK4 is inhibited by the interaction of the kinase domain with a newly defined pseudosubstrate sequence (PS) within the PAK4 regulatory domain. In this model, the binding of SH3 domain-containing proteins to the PS releases the catalytic domain, thereby promoting kinase activity 130 . It is thought that PAK5 and PAK6 also follow this model, but this has not been experimentally verified.
GTPase-activating proteins (GAPs). Proteins that accelerate the hydrolysis of GTP to GDP, which leads to an increase in the proportion of GDP-bound GTPase molecules and a consequent reduction in their activity.
Guanine nucleotide dissociation inhibitors
(GDIs). Enzymes that sequester GDP-bound small GTPases in the cytoplasm.
from those that are used by group I PAKs; for example, PAK4 has been shown to inhibit apoptosis by inhibiting an early apoptotic molecule, caspase 8, through a kinase-independent mechanism 51 .
Activating invasion and metastasis
Tumour cell migration and invasion are key factors in metastatic distribution to distant organs. The initial stages of these processes involve extensive remodelling of the cytoskeleton, disruption of cell adhesions and release of proteases that digest the extracellular matrix. PAKs have an important role in regulating these events, which are mediated by a number of cytoskeletal effector proteins, including GEFs, GTPase-activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs), which control RHO family GTPases, and by proteins that more directly function on actin (FIG. 1) .
As part of a protein complex containing the RAC GEF β-PIX (also known as ARHGEF7), the ARF GAP GIT1, and the adaptor protein paxillin, PAK1 induces rapid turnover of focal contacts at the leading edge of cells, which promotes increased cell motility [52] [53] [54] . The molecular events that underlie this process involve the phosphorylation of paxillin by PAK1, which is an event that augments the association of paxillin and GIT1 and that targets the GIT1-β-PIX-PAK signalling module to the leading edge of the cell. In agreement with this model, the expression of dominant-negative PAK1 in invasive breast carcinoma cell lines is associated with decreased invasion and migration, and these cells have stable focal adhesions, increased stress fibres and increased cell attachment 55 . LIM domain kinase 1 (LIMK1) is another important target for PAK in actin remodelling. PAK1 phosphorylates and activates LIMK1, which subsequently phosphory lates cofilin at Ser3, and this event inhibits the ability of cofilin to sever and depolymerize actin filaments 56 . Such regulation of cofilin by the PAK1-LIMK1 pathway is required for RAC1-induced actin reorganization at the leading edge of the cell 56 . This activity may be specific to particular PAK isoforms; this idea has arisen because in breast carcinoma cells it has been reported that PAK1, but not PAK2, mediates the formation of heregulin-stimulation of lamellipodial protrusions, the maturation of focal adhesions, cofilin phosphorylation and the loss of RHOA activity 57 . A similar dichotomy regarding PAK isoforms and cytoskeletal activity has been shown in mast cells, in which PAK1 and PAK2 seem to have opposing roles with respect to actin organization and degranulation 58, 59 . Tumour cell invasion also requires the reorganization of the extracellular matrix to provide space for cell movement. Destruction of the extracellular matrix is partly controlled by the release of matrix metalloproteinases (MMPs). Genetic experiments suggest that PAK mediates certain aspects of extracellular matrix organization downstream of CDC42, as matrix remodelling could not be restored to Cdc42 −/− mouse embryonic fibroblasts (MEFs) by reintroducing mutants of CDC42 that lacked PAK binding 60 . PAK1, PAK2, PAK4 and PAK5 have been shown to regulate MMP expression in various cancer cell types [61] [62] [63] [64] . Increased expression of MMPs has been suggested to result from PAK-mediated activation of JUN N-terminal kinase (JNK) 65, 66 . PAK4 has also been reported to interact with MMP2, and knockdown of PAK4 in glioma cell lines is associated with downregulation of MMP2, decreased migration and loss of invasiveness 64 . In addition, recent work has shown that PAK1 knockdown in prostate cancer cells was associated with reduced motility, reduced MMP9 secretion and increased expression of transforming growth factor-β (TGFβ; which in these cases is growth inhibitory) 67, 68 . Interestingly, in these cells PAK1 seemed to be the major PAK isoform that was required for invasiveness, despite the prominent expression of group II PAK4 and PAK6 (REFS 34,67,69).
Box 2 | PAK gene amplification
The amplification of p21-activated kinase (PAK) genes is the most well-described mechanism for increased PAK function in cancer; for example, amplification of chromosomal region 11q13, which contains PAK1, has been reported in various human cancers, including a large percentage (about 30%) of breast and ovarian cancers 7, 131, 132 (see the figure) . In breast cancer, amplification of 11q13 is associated with poor prognosis, and there is much interest in identifying driver genes within this region 132 . PAK1 amplification is also prevalent in melanomas that lack BRAF mutations 96 . This finding along with reports of activating mutations in the group I PAK activator RAC1 in melanoma 133, 134 suggest that certain BRAF-wild-type forms of melanoma might also be driven by PAK1 activation.
The 11q13 amplicon comprises multiple subclusters of amplified genes, many of which have been implicated in breast cancer, including CCND1 (encoding cyclin D1) [135] [136] [137] . As PAK1 signalling augments cyclin D1 expression, perhaps via its transcriptional activators β-catenin 26, 102 and/or ERK, it is possible that co-amplification of PAK1 and CCND1 has a cooperative effect. It is also interesting that several other genes within the amplified cluster encode proteins that activate ERK or that function in the DNA repair pathway, which indicates potential oncogenic interactions with PAK1.
The PAK4 gene also occurs within a chromosomal region (19q13.2) that is commonly amplified in human malignancies -in particular, in 10-20% of pancreatic cancer, oral squamous cell carcinoma, basal-like breast cancer, and serous and endometrioid ovarian cancer [138] [139] [140] [141] . Amplification of PAK4 is associated with aggressive disease and poor prognosis 138 . Cells that overexpress PAK4 are sensitive to PAK4 knockdown by small interfering RNA 140, 142, 143 , which implies that an oncogene-addicted state occurs in such cells. Interestingly, the peak of the 19q13 amplicon includes CCNE1 (encoding cyclin E1), and this genomic arrangement is physically, and perhaps functionally, analogous to the proposed relationship between CCND1 and PAK1 on chromosome 11. In addition, similar to PAK1, transgenic overexpression of PAK4 is sufficient to drive mammary tumorigenesis in three-dimensional cultures and in xenografts 144 , and this is consistent with the idea that overexpression of the wild-type allele alone can be sufficient for transformation in the appropriate cellular setting.
Amplification peaks (see the figure) correspond to q values from the GISTIC (Genomic Identification of Significant Targets in Cancer) analysis presented on the Broad Institute Tumorscape website (see Further information). The plots were generated from q values using Microsoft Office Excel. ARHGAP33, RHO GTPase-activating protein 33; ARHGEF17, RHO guanine nucleotide exchange factor 17; CDC42BPG, CDC42 binding protein kinase-γ; CDC42EP2, CDC42 effector protein 2; DYRK1B, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B; FADD, FAS (TNFRSF6)-associated via death domain; GAB2, GRB2-associated binding protein 2; NFKBIB, nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor-β; PSMC4, proteasome (prosome, macropain) 26S subunit, ATPase, 4; RSF1, remodelling and spacing factor 1; TGFB, transforming growth factor-β1. Nature Reviews | Cancer 0 , T h r 1 7 3 a n d S e r 2 3 9 S e r 3 4 2 a n d T h r2 8 8 PAK and angiogenesis PAK involvement in endothelial cell biology and angiogenesis has been under scrutiny owing to the wellestablished role of these enzymes in cell proliferation, cytoskeleton rearrangement and migration 20, 70, 71 . In mouse models, molecules that signal both upstream and downstream of PAK have been shown to be crucial for vasculogenesis and angio genesis [72] [73] [74] . For example, endothelial knockout of Rac1 or Cdc42 is lethal during mouse development, and this is associated with an impaired formation of blood vessels 72, 74 . Furthermore, adult primary endothelial cells that lack Rac1 or Cdc42, show impaired proliferation, attachment, migration and angiogenesis 72, 74 . Whether these effects are mediated through any of the PAKs is not known; however, both Pak2-and Pak4-knockout mice are embryonic lethal as a result of multiple organogenesis defects, including severe cardiovascular abnormalities 75, 76 . Recent studies from our group show that endothelial-specific deletion of Pak2 is associated with death at embryonic day 9.5 and with grossly impaired blood vessel formation in both the embryo body and the yolk sac (M.R. and J.C., unpublished observations). By contrast, there is no notable vascular phenotype in Pak1-null mice 75 . It should be noted that PAK2 is the main isoform that is expressed in endothelial cells. For this reason, even though PAK1 and PAK2 might have different (and perhaps even opposing) cellular functions 26, 58 , most of the current evidence favours the idea that PAK2 is the more relevant mediator of angiogenic signalling downstream of RHO family GTPases.
Proliferation, survival, migration and tube formation.
In breast cancer cells, it has been shown that PAK1 is required for vascular endothelial growth factor (VEGF) expression downstream of an activator of ERBB signalling, heregulin, thereby promoting angiogenesis 77 . Data from another group showed that the ability of PAK1 to phosphorylate myosin light chain (MLC) is crucial for the endothelial cell cytoskeletal dynamics that mediate migration 78 . Furthermore, various scaffolding proteins, including NCK adaptor protein 1 (NCK1) and filamin B, have been shown to form protein complexes that are essential during PAK1-and PAK4-mediated endothelial migration 79, 80 . PAK1 and PAK4 have been found to modulate CRAF and BAD phosphorylation levels and to inhibit apoptosis in endothelial cells 13, 81 . With respect to blood vessel lumen formation, PAK2 and PAK4 are required for this process in vitro, functioning in a pathway that involves RHO GTPases, SRC, protein kinase Cε (PKCε) and CRAF 82, 83 (FIG. 3) . It has also been suggested that PAK4 has a role in angiogenesis through the phosphorylation of αvβ5 integrin, which affects endothelial cell motility and permeability 84 . . However, it is not clear whether PAK promotes or reduces permeability, or does both. In a hypoxia-induced hypertension model, the activation of RAC-PAK signalling has been shown to protect against a hypoxia-induced increase in vascular permeability 86 . Consistent with these findings, inactivating mutations in zebrafish Pak2a (a gene encoding a protein that is highly homologous to human PAK2) or in its binding partner arhgef7b (which encodes β-PIX) are associated with brain haemorrhage due to immature vasculature and improper endothelial-mesenchymal contacts 87 . However, it has also been shown that group I PAK signalling leads to an increase in vascular permeability by modulating cell contraction. It was proposed that a PAK-β-PIX-GIT1 complex induces phosphoryl ation of MLC, which results in a contracted cell that has permeable cell junctions 88, 89 . Other studies have suggested that PAK promotes endothelial permeability: they have shown that PAK1 can phosphorylate vascular endothelialcadherin (VE-cadherin). Upon phosphory lation by PAK1, VE-cadherin dissociates from β-arrestin 2 and translocates from cell-cell junctions to the cytoplasm, which weakens endothelial cell-cell contacts and increases vascular permeability 90, 91 (FIG. 3) .
Whether PAKs help or hinder endothelial barrier function could have important clinical implications because the effects of small-molecule PAK inhibitors might resemble those that are seen in gene disruption studies. It is possible that PAK has both functions, depending on context and isoform, and these issues should be resolved as more endothelial-specific PAK-knockout mice become available for study.
PAK-targeting therapeutics
Although several broad-range kinase inhibitors show potent PAK inhibition 92, 93 , such non-selective compounds have limited use. As PAKs are increasingly control crucial cellular events that are required for angiogenesis, including endothelial cell proliferation, survival, attachment and migration. In endothelial cells, the phosphorylation (P) of BAD and CRAF by PAK protects against apoptotic stimuli by promoting the translocation of CRAF to mitochondria and the displacement of BAD-BCL-2 complexes. As seen in other cellular contexts, in endothelial cells the ERK pathway regulates cellular proliferation and migration when it is initiated by the activation of the RAC-PAK pathway. The control of vascular permeability by PAK is mediated by modulation of cellular contractility and cell-cell adhesion molecules. In one model, direct phosphorylation of myosin light chain (MLC) by PAK leads to increased contractility and increased endothelial permeability, and this has been shown in certain experimental settings. PAK has also been proposed to disrupt endothelial cell-cell junctions by direct phosphorylation and subsequent internalization and degradation of vascular endothelial-cadherin (VE-cadherin). In another model, activated PAK phosphorylates and inhibits guanine nucleotide exchange factor H1 (GEFH1), which leads to decreased RHOA-RHO-associated protein kinase (ROCK)-MLC activity, decreased contractility and decreased endothelial permeability. This model is consistent with data showing that PAK protects against an increase in permeability in a hypoxia-induced pulmonary hypertension model and in a Pak2a-knockout zebrafish model (dashed arrows). bFGF, basic fibroblast growth factor; CDC42, cell division control protein 42; CDKs, cyclin-dependent kinases; FAK, focal adhesion kinase; GIT1, ARF GTPase-activating protein; NCK1, NCK adaptor protein 1; TNFα, tumour necrosis factor-α; VEGF, vascular endothelial growth factor. Nature Reviews | Cancer 
Drug efflux
The ability to actively pump out certain small-molecule inhibitors from cells.
recognized as plausible targets for cancer therapeutics, the search for both pan-PAK inhibitors and groupspecific PAK inhibitors has intensified. However, this task has proved particularly challenging for the PAKs as a result of the large size and high flexibility of the catalytic pocket as well as gaps in our understanding of PAKs regulation.
Although it was originally designed as a PAK4 inhibitor, a potent ATP-competitive pyrrolopyrazole PAK inhibitor, PF-3758309, efficiently targets both group I and II PAKs, as well as a number of other (off-target) kinases 94 (FIG. 4) . PF-3758309 inhibits the growth of many types of tumour cell lines and has also shown potent anticancer properties in xenografts and in a KRASdriven transgenic mouse model of skin cancer 24, [94] [95] [96] . Although the signalling effects of this compound in vivo resemble those in Pak1-knockout mice 24 , it remains difficult to ascribe these desirable biological effects to PAK inhibition alone. This will need to be shown using more PAK-specific analogues of PF-3758309, or experiments showing that drug-resistant PAK alleles can overcome PF-3758309-mediated tumour growth inhibition. Despite these issues, the suitable potency (half-maximal inhibitory concentration (IC 50 ) ~4.7 nM) of PF-3758309, combined with its oral availability, led to its advancement to Phase I clinical trials.
However, PF-3758309 was withdrawn from clinical use as a result of undesirable pharmacological properties: most prominently, excessive drug efflux 97 . A group I-specific ATP-competitive PAK inhibitor, FRAX-597, was recently shown to reduce the initiation and progression of KRAS-driven tumours in a mouse model of skin cancer, as well as to reduce the growth of merlin-deficient schwannoma xenografts 24, 98 . However, this compound has substantial off-target activity against receptor tyrosine kinases (FIG. 4) . Surprisingly, treatment with FRAX-597 has been shown to result in reduction of total PAK1 and PAK2 levels, and this effect is abolished in cells that are treated with the proteasome inhibitor MG132 (H.-Y. Chow and J.C., unpublished observations), which suggests that FRAX-597 functions not only as an ATP-competitive inhibitor but also as a PAKdestabilizing agent. Such a combination of inhibitory mechanisms -competition with ATP and destabilization of the kinase -are particularly attractive features of this compound and might be exploited in more specific future analogues.
In an attempt to exploit the capacious ATP-binding pocket that is present in all of the PAKs, a metallopyridocarbazole scaffold has been used to position a rigid, bulky ruthenium complex within the ribosebinding site 99 . The resulting compound, known as FL172, 
TAT peptide
A cell-penetrating peptide that is derived from the HIV TAT protein, which, when fused to a peptide of interest, allows the fusion peptide to penetrate cell membranes and therefore enter cells.
Protein microarray screens
Recombinant proteins that are arrayed on a surface such as a glass slide and that can be assessed for phosphorylation that follows incubation with a protein kinase and ATP.
efficiently fills the large catalytic pocket, thereby gaining high PAK1 inhibitory efficacy (IC 50 ~1 μM), as well as reasonably high selectivity over other related protein kinases. Among the 264 kinases that were tested, only 15 showed an inhibition that was similar to that of PAK1 (FIG. 4) . However, compounds like FL172 that are based on organometallic conjugates usually suffer from poor solubility and relatively high toxicity, and it is therefore unclear whether this strategy will yield clinically useful inhibitors.
Attempts to develop allosoteric PAK inhibitors have also been described 100 . For example, IPA-3 (inhibitor p21-activated kinase-3), which is a sulphhydrylcontaining compound that targets the amino-terminal regulatory domain of group I PAKs, was isolated in a deliberate attempt to identify non-competitive PAK1 inhibitors 100 . Reversible covalent binding of IPA-3 to the PAK1 regulatory domain prevents GTPase docking and the subsequent switch to a catalytically active state 101 . This unique mechanism of function probably accounts for the exceptional target specificity of IPA-3, which is a property that makes it useful as a tool compound for in vitro research and as a proof of concept. However, the pharmacokinetic properties of the compound, as well as undesirable redox effects in cells due to the continuous reduction of the sulphhydryl moiety, makes IPA-3 unsuitable for further clinical development.
Apart from the small-molecule drugs, PAK allosteric peptide inhibitors have been widely used as laboratory tools. Although the isolated PAK1 autoinhibitory domain (AID) (BOX 1) efficiently regulates PAK1 function, the need to deliver the peptide into cells makes the approach challenging for therapeutic use. Moreover, induction of cell cycle arrest by the PAK1 AID can occur without the inhibition of PAK1 kinase activity 102 , most probably as a result of AID binding to the fragile-X proteins FMR1 and FRX1, which modulate the stability of the cell cycle inhibitor p21 (REFS 103, 104) . However, the AID that is derived from PAK2 lacks FMR1 and FXR1 binding and presumably exerts its biological effects only through PAK inhibition. Two other peptide inhibitors, comprising the cell permeant TAT peptide fused to the β-PIX-interacting motif (TAT-PAK18) or fused to the NCK1-binding motif of PAK1, have also been described. These peptides are thought to prevent proper cellular localization (and activation) of PAK1 through the disruption of PAK1-NCK1 or PAK1-β-PIX interactions. The PAK-mediated growth suppression effect of TAT-PAK18 has been shown using PAK1-dependent ovarian cancer cell lines 105 , while a TAT-NCK1-binding inhibitory peptide affects endothelial cell migration and contractility 83, 106 .
Conclusions and future directions
PAKs occupy a central position in oncogenic signalling: they drive several processes that are the hallmarks of cancer initiation, growth and spread. In proliferative signalling, PAK activity is required for the efficient activation of ERK, AKT and β-catenin in many tissues. These effects may make cells particularly sensitive to specific small-molecule inhibitors of PAK.
With respect to determining the role of PAKs in cancer, we have a reasonable knowledge of the signalling framework, but some basic questions remain unanswered. The foremost of these are the identities of the most relevant substrates and whether these are unique to individual members of the PAK family. What is needed are more comprehensive and unbiased approaches for substrate identification. Efforts in this direction have already begun and have used diverse technologies such as protein microarray screens 107, 108 , substrate capture 109 and phosphoproteome signatures 110 , but additional important substrates undoubtedly remain to be discovered. It will also be important to more clearly distinguish scaffolding from catalytic functions, as only catalytic functions are expected to be blocked by conventional small-molecule inhibitors.
What types of cancers might benefit from PAK inhibitors? We suggest three scenarios. First, given the seeming addiction of PAK-amplified cells to PAK activity, we suggest that tumours that have chromosome 11q13 or chromosome 19q13 amplifications
-which are commonly found in breast, ovarian and pancreatic cancer -should be particularly susceptible to small-molecule inhibitors of group I and group II PAKs, respectively. In addition, the genomic organization of these amplicons suggests that such tumours might also have synergistic responses to combined inhibition of PAK and signalling proteins that drive cell cycle progression, as genes that encode cyclins are frequently co-amplified with PAKs. Second, because oncogenic signals from ERBB2, KRAS and merlin have been shown to depend on PAK1 function in mouse models, tumours that are driven by mutations in the genes that encode these proteins might also be good candidates for PAK-targeted therapeutics. Third, the stabilization of β-catenin by PAK1 suggests that tumours that depend on overactive WNT signalling, such as most colon cancers, might also respond well to PAK inhibitors. As with other therapeutics that target signalling proteins, it is likely that PAK inhibitors will prove to be most useful in combination with other targeted drugs, as has been suggested in xenograft models 8, 26 . Owing to the structural characteristics of their catalytic domains, the PAKs, and in particular the group I PAKs, are challenging targets with respect to the development of specific competitive inhibitors, but recent progress using various chemical scaffolds suggests that this challenge can be met. In addition, the unusual activation mechanisms for both PAK subgroups
provide opportunities for the further development of allosteric inhibitors. Whether competitive or noncompetitive, such inhibitors will need to be used with caution because mouse models indicate that certain PAK functions -in particular, maintenance of normal vascular permeability and haematopoietic stem cell function -may be required even in adult animals 111, 112 (TABLE 1). Although it is important to acknowledge these provisos, the central position of PAKs in key oncogenic signalling pathways and their potential tractability as drug targets make these enzymes worthy of increased study by the community of cancer cell biologists and by the pharmaceutical industry.
